But hope to get result soon
Tirzepatide causes nausea primarily because it slows gastric emptying the rate at which food moves from the stomach into the small intestine
The ATTAIN-MAINTAIN trial validated that patients can switch from tirzepatide to orforglipron and maintain their weight loss, establishing a potential sequential treatment paradigm: injectable first for maximum loss, then oral maintenance
Researchers are still learning about GLP-1s other potential uses, and more market growth is expected
Furthermore, treatment with this oxidative phosphorylation inhibitor drug was demonstrated to significantly radiosensitise radioresistant oesophageal adenocarcinoma cells to clinically-relevant doses of X-ray radiation (21)
By targeting these biological pathways, GLP-1 therapy may support consistent, medically supervised weight management for appropriate individuals